BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24312317)

  • 1. The effect of a maturing antiretroviral program on early mortality for patients with advanced immune-suppression in Soweto, South Africa.
    Otwombe KN; Laher F; Tutu-Gxashe T; Gray G; Mohapi L
    PLoS One; 2013; 8(11):e81538. PubMed ID: 24312317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
    Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
    PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria.
    Lessells RJ; Mutevedzi PC; Iwuji CC; Newell ML
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):e17-24. PubMed ID: 23756374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
    Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
    PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults.
    Mutevedzi PC; Lessells RJ; Rodger AJ; Newell ML
    PLoS One; 2011; 6(7):e21795. PubMed ID: 21747959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.
    Cornell M; Johnson LF; Wood R; Tanser F; Fox MP; Prozesky H; Schomaker M; Egger M; Davies MA; Boulle A;
    J Int AIDS Soc; 2017 Sep; 20(1):21902. PubMed ID: 28953328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.
    Maskew M; Fox MP; van Cutsem G; Chu K; Macphail P; Boulle A; Egger M; Africa FI
    PLoS One; 2013; 8(6):e64392. PubMed ID: 23755122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late?
    Innes S; Lazarus E; Otwombe K; Liberty A; Germanus R; Van Rensburg AJ; Grobbelaar N; Hurter T; Eley B; Violari A; Cotton MF
    J Int AIDS Soc; 2014; 17(1):18914. PubMed ID: 24925044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.
    Clouse K; Pettifor A; Maskew M; Bassett J; Van Rie A; Gay C; Behets F; Sanne I; Fox MP
    AIDS; 2013 Feb; 27(4):645-50. PubMed ID: 23169326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa.
    Lawn SD; Little F; Bekker LG; Kaplan R; Campbel E; Orrell C; Wood R
    AIDS; 2009 Jan; 23(3):335-42. PubMed ID: 19114870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
    Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
    AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study.
    Bor J; Ahmed S; Fox MP; Rosen S; Meyer-Rath G; Katz IT; Tanser F; Pillay D; Bärnighausen T
    PLoS One; 2017; 12(6):e0178249. PubMed ID: 28617805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss to care and death before antiretroviral therapy in Durban, South Africa.
    Bassett IV; Wang B; Chetty S; Mazibuko M; Bearnot B; Giddy J; Lu Z; Losina E; Walensky RP; Freedberg KA
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):135-9. PubMed ID: 19504725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial.
    Rosen S; Maskew M; Fox MP; Nyoni C; Mongwenyana C; Malete G; Sanne I; Bokaba D; Sauls C; Rohr J; Long L
    PLoS Med; 2016 May; 13(5):e1002015. PubMed ID: 27163694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi.
    Brown JP; Ngwira B; Tafatatha T; Crampin AC; French N; Koole O
    AIDS Res Ther; 2016; 13():24. PubMed ID: 27398087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.
    Boyer S; Iwuji C; Gosset A; Protopopescu C; Okesola N; Plazy M; Spire B; Orne-Gliemann J; McGrath N; Pillay D; Dabis F; Larmarange J;
    AIDS Care; 2016; 28 Suppl 3(Suppl 3):39-51. PubMed ID: 27421051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis.
    Rabie H; Violari A; Duong T; Madhi SA; Josipovic D; Innes S; Dobbels E; Lazarus E; Panchia R; Babiker AG; Gibb DM; Cotton MF;
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1194-200, i. PubMed ID: 21943845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation.
    Lawn SD; Myer L; Harling G; Orrell C; Bekker LG; Wood R
    Clin Infect Dis; 2006 Sep; 43(6):770-6. PubMed ID: 16912954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.